Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells

American Journal of Physiology - Endocrinology and Metabolism

Volumn 296, Issue 3, 2009, Pages

  Vitale, Giovanni ^a   Van Koetsveld, Peter M ^a   De Herder, Wouter W ^a   Van Der Wansem, Katy ^a   Janssen, Joop A M J L ^a   Colao, Annamaria ^b   Lombardi, Gaetano ^b   Lamberts, Steven W J ^a   Hofland, Leo J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Insulin like growth factor I receptor; Insulin like growth factor II; Neuroendocrine tumors; Type I interferons

Indexed keywords

BETA1A INTERFERON; INSULIN RECEPTOR; MESSENGER RNA; RECOMBINANT ALPHA2B INTERFERON; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BETA INTERFERON; IMMUNOLOGIC FACTOR;

APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CELL PROLIFERATION; CONTROLLED STUDY; DNA FRAGMENTATION; DOWN REGULATION; HUMAN; HUMAN CELL; NEUROSECRETORY CELL; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; UPREGULATION; CELL DIVISION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEUROENDOCRINE TUMOR; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SECRETION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; AUTOCRINE COMMUNICATION; CELL DIVISION; CELL LINE, TUMOR; DNA FRAGMENTATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOLOGIC FACTORS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; INTERFERON-ALPHA; INTERFERON-BETA; NEUROENDOCRINE TUMORS; PARACRINE COMMUNICATION; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; RNA, MESSENGER;

EID: 64749099940     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.90770.2008     Document Type: Article

References (36)

1. Breuhahn K, Vreden S, Haddad R, Beckebaum S, Stippel D, Flemming P, Nussbaum T, Caselmannn WH, Haab BB, Schirmacher P. Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression. Cancer Res 64: 6058-6064, 2004. (Pubitemid 39129404)
2. Brugts MP, van den Beld AW, Hofland LJ, van der Wansem, van Koetsveld PM, Frystyk J, Lamberts SW, Janssen JA. Low circulating IGF-I bioactivity in elderly men is associated with increased mortality. J Clin Endocrinol Metab 93: 2515-2522, 2008.
3. Caraglia M, Marra M, Pelaia G, Maselli R, Caputi M, Marsico SA, Abbruzzese A. Alpha-interferon and its effects on signal transduction pathways. J Cell Physiol 202: 323-335, 2005. (Pubitemid 40041303)
4. Caraglia M, Passeggio A, Beninati S, Leardi A, Nicolini L, Improta S, Pinto A, Bianco AR, Tagliaferri P, Abbruzzese A. Interferon alpha2 recombinant and epidermal growth factor modulate proliferation and hypusine synthesis in human epidermoid cancer KB cells. Biochem J 324: 737-741, 1997. (Pubitemid 27285530)
5. Chacko MS, Adamo ML. Double-stranded RNA decreases IGF-I gene expression in a protein kinase R-dependent, but type I interferon-independent, mechanism in C6 rat glioma cells. Endocrinology 143: 525-534, 2002.
6. Coradini D, Biffi A, Pirronello E, Di Fronzo G. The effect of α-, β- and λ-interferon on the growth of breast cancer cell lines. Anticancer Res 14: 1779-1784, 1994.
7. Croze E, Russell-Harde D, Wagner TC, Pu H, Pfeffer LM, Perez HD. The human type I interferon receptor. Identification of the interferon beta-specific receptor-associated phosphoprotein. J Biol Chem 271: 33165-33168, 1996. (Pubitemid 27010335)
8. Damdinsuren B, Nagano H, Sakon M, Kondo M, Yamamoto T, Umeshita K, Dono K, Nakamori S, Monden M. Interferon-β is more potent than interferon-α in inhibition of human hepatocellular carcinoma cell growth when used alone and in combination with anticancer drugs. Ann Surg Oncol 10: 1184-1190, 2003. (Pubitemid 40486814)
9. Del Monte P, Laurino C, Arvigo M, Palermo C, Minuto F, Barreca A. Effects of α-interferon on insulin-like growth factor-I, insulin-like growth factor-II and insulin-like growth factor binding protein-3 secretion by a human lung cancer cell line in vitro. J Endocrinol Invest 28: 432-439, 2005. (Pubitemid 43162740)
10. Denley A, Cosgrove LJ, Booker GW, Wallace JC, Forbes BE. Molecular interactions of the IGF system. Cytokine Growth Factor Rev 16: 421-439, 2005. (Pubitemid 41022012)
11. Ferone D, Pivonello R, van Hagen PM, Dalm VA, Lichtenauer-Kaligis EG, Waaijers M, van Koetsveld PM, Mooy DM, Colao A, Minuto F, Lamberts SW, Hofland LJ. Quantitative and functional expression of somatostatin receptor subtypes in human thymocytes. Am J Physiol Endocrinol Metab 283: E1056-E1066, 2002.
12. Giandomenico V, Vaccari G, Fiorucci G, Precario Z, Vannuchi S, Matarrese P, Malori W, Romeo G, Affabris GR. Apoptosis and growth inhibition of squamous carcinoma cells treated with interferon-α, interferon-β and retinoic acid are associated with induction of the cyclin-dependent kinase inhibitor p21. Eur Cytokine Netw 9: 619-631 1998. (Pubitemid 29033929)
13. Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de HerderWW, Beckers A, Lamberts SW. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 152: 645-654, 2005. (Pubitemid 40575811)
14. Hofland LJ, van Koetsveld PM, Lamberts SW. Percoll density gradient centrifugation of rat pituitary tumor cells: a study of functional heterogeneity within and between tumors with respect to growth rates, prolactin production and responsiveness to the somatostatin analog SMS 201-995. Eur J Cancer 26: 37-44, 1990.
15. Hopfner M, Baradari V, Huether A, Schofl C, Scherubl H. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocr-Relat Cancer 13: 135-149, 2006.
16. Horikoshi T, Fukuzawa K, Hanada N, Ezoe K, Eguchi H, Hamaoka S, Tsujiya H, Tsukamoto T. In vitro comparative study of the antitumor effects of human interferon-α, β and λ on the growth and invasive potential of human melanoma cells. J Dermatol 22: 631-636, 1995.
17. Kanaley JA, Frystyk J, Moller N, Dall R, Chen JW, Nielsen SC, Christiansen JS, Jorgensen JOL, Flyvbjerg A. The effect of submaximal exercise on immuno- and bioassayable IGF-I activity in patients with GH-deficiency and healthy subjects. Growth Horm IGF Res 15: 283-290, 2005. (Pubitemid 41093733)
18. LeRoith D, Roberts CT. The insulin-like growth factor system and cancer. Cancer Lett 195: 127-137, 2003. (Pubitemid 36588961)
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2[-Delta Delta C(T)] method. Methods 25: 402-408, 2001.
20. Lu W, Su J, Kim LS, Bucana CD, Donawho C, He J, Fidler IJ, Dong Z. Active specific immunotherapy against occult brain metastasis. Cancer Res 63: 1345-1350, 2003. (Pubitemid 36348715)
21. Mager DE, Neuteboom B, Jusko WJ. Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys. Pharm Res 22: 58-61, 2005.
22. Nilsson O, Wangberg B, Theodorsson E, Skottner A, Ahlman H. Presence of IGF-I in human midgut carcinoid tumours: an autocrine regulator of carcinoid tumour growth? Int J Cancer 51: 195-203, 1992.
23. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature (Lond) 406: 747-752, 2000.
24. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 202: 8-32, 2004. (Pubitemid 39576902)
25. Platanias LC, Fish EN. Signaling pathways activated by interferons. Exp Hematol 27: 1583-1592, 1999.
26. Quinn KA, Treston AM, Unsworth EJ, Miller MJ, Vos M, Grimley C, Battey J, Mulshine JL, Cuttitta F. Insulin-like growth factor expression in human cancer cell lines. J Biol Chem 271: 11477-11483, 1996. (Pubitemid 26155990)
27. Rosenblum MG, Yung WKA, Kelleher PJ, Ruzicka F, Steck PA, Borden EC. Growth inhibitory effects of interferon-β but not interferon-α on human glioma cells: correlation of receptor binding 2′,5′- oligoadenylate synthetase and protein kinase activity. J Interferon Res 10: 141-151, 1990. (Pubitemid 20138707)
28. Shahjee H, Bhattacharyya N, Zappala G, Wiench M, Prakash S, Rechler MM. An N-terminal fragment of insuline-like growth factor binding protein-3 (IGFBP-3) induces apoptosis in human prostate cancer cells in an IGF-independent manner. Growth Horm IGF Res 18: 188-197, 2008.
29. Thulasi R, Dias P, Houghton PJ, Houghton JA. Alpha 2a-interferon-induced differentiation of human alveolar rhabdomyosarcoma cells: correlation with down-regulation of the insulin-like growth factor type I receptor. Cell Growth Differ 7: 531-541, 1996. (Pubitemid 26362097)
30. Van der Wal BC, Hofland LJ, Marquet RL, van Koetsveld PM, van Rossen ME, van Eijck CH. Paracrine interactions between mesothelial and colon-carcinoma cells in a rat model. Int J Cancer 73: 885-890, 1997.
31. van Koetsveld PM, Vitale G, de Herder WW, Feelders RA, van der Wansem K, Waaijers M, van Eijck CH, Speel EJ, Croze E, van der Lely AJ, Lamberts SW, Hofland LJ. Potent inhibitory effects of type I interferons on human adrenocortical carcinoma cell growth. J Clin Endocrinol Metab 91: 4537-4543, 2006.
32. Vitale G, de Herder WW, van Koetsveld PM, Waaijers M, Schoordijk W, Croze E, Colao A, Lamberts SW, Hofland LJ. IFN-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro. Cancer Res 66: 554-562, 2006. (Pubitemid 43166064)
33. Vitale G, van Eijck CH, van Koetsveld PM, Erdmann J, Speel EJ, van der Wansem K, Mooij DM, Colao A, Lombardi G, Croze E, Lamberts SWJ, Hofland LJ. Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors. Ann Surg 246: 259-268, 2007. (Pubitemid 47196524)
34. von Wichert G, Haeussler U, Green FR, Kliche S, Dralle H, Bohm B O, Adler G, Seufferlein T. Regulation of cyclin D1 expression by autocrine IGF-I in human BON neuroendocrine tumour cells. Oncogene 24: 1284-1289, 2005. (Pubitemid 40313930)
35. von Wichert G, Jehle PM, Hoeflich A, Koschnick S, Dralle H, Wolf E, Wiedenmann B, Boehm B, Adler G, Seufferlein T. Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res 60: 4573-4581, 2000. (Pubitemid 32103642)
36. Wulbrand U, Remmert G, Zofel P, Wied M, Arnold R, Fehmann HC. mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours. Eur J Clin Invest 30: 729-739, 2000. (Pubitemid 30604075)